Strides Pharma Science Share Price

NSE: STAR

₹ 1,016.00

-₹15.60 (-1.51%)

Last updated 24 Jul, 2026, 15:29 IST

Strides Pharma Science Share Price Today

As of 25 Jul 2026, Strides Pharma Science share price is ₹1,016.00. The stock opened at ₹1,031.60, compared to its previous close of ₹1,031.60. During today's trading session, Strides Pharma Science share price moved in the range of ₹1,014.60 to ₹1,034.40, with an average price of ₹1,024.50 for the day. Looking at its last 52-week, the stock has touched a low of ₹768.65 and a high of ₹1,231.00. On the performance front, Strides Pharma Science share price has increased by 28.10% over the last six months and is up 10.84% on a year-on-year basis.

₹1,014.60

1.51% down today

₹1,034.40

1D LOW

1D HIGH

Latest Earning

Op Profit TrendUp by 37.33% YoY

Latest Earning

Net Profit TrendDown by 37.88% QoQ

Latest Earning

Revenue TrendUp by 2.31% QoQ

Stock Performance

OutperformingBeat Nifty by 34.9 % in last 6 month

Shareholding Pattern

DIIDII increased stake by 13.56%

Shareholding Pattern

FIIFII decreased stake by 1.00%

Strides Pharma Science Returns Calculator

If you would've invested

₹

₹1,000₹1Cr

Historical Returns

1 Year

₹5,59,379+₹59,379 (+11.88%)

3 Year

₹10,75,929+₹5,75,929 (+115.19%)

5 Year

₹6,59,312+₹1,59,312 (+31.86%)

₹825.30₹1,237.90

Circuit Low

Circuit High

₹768.65₹1,231.00

52-Week Low

52-Week High

Circuit

₹825.30

₹1,237.90

52-week

₹768.65

₹1,231.00

Mkt Cap Cr

9,392.40

P/E

16.53

P/B

3.06

ROE

17.90%

D/E

0.37

ROCE

17.30%

Div. Yield

0.53%

EPS(TTM)

19.92

Turnover

0.61

EV/EBITDA

10.61

Net Margin

3.37%

Op. Margin

14.11%

ROA

8.29%

Quick Ratio

0.97

Curr. Ratio

1.36

Mkt Cap Cr

9,392.40

P/E

16.53

P/B

3.06

ROE

17.90%

D/E

0.37

ROCE

17.30%

Div. Yield

0.53%

EPS(TTM)

19.92

Turnover

0.61

EV/EBITDA

10.61

Net Margin

3.37%

Op. Margin

14.11%

ROA

8.29%

Quick Ratio

0.97

Curr. Ratio

1.36

Based on fundamentals, this stock's

Performance

Very Poor

Strides Pharma has not beaten FD return of 7%

Valuation

Fairly Valued

Strides Pharma appears to be fairly valued compared to its peers

Earnings

Neutral

Strides Pharma earnings growth is positive

Peer Comparison

Peer comparison — key ratios
Name	Mkt Cap Cr	P/E	P/B	ROE	D/E	ROCE	Book Value	Div. Yield	Turnover	EPS(TTM)
Sun Pharmaceutical Industries	4,65,711.00	36.73	5.05	14.85%	0.55	18.72%	18.85	0.91%	0.56	10.90
Divis Laboratories	1,93,860.00	61.36	9.40	16.19%	0.00	21.00%	9.43	0.50%	0.58	98.19
Torrent Pharmaceuticals	1,92,687.00	66.03	17.03	26.76%	1.05	18.30%	16.90	0.90%	0.49	64.75
Cipla	1,12,593.00	33.55	3.27	11.27%	0.00	14.95%	423.36	0.93%	0.44	43.52
Zydus Lifesciences	1,11,082.00	17.39	3.23	19.69%	0.35	20.30%	3.70	0.11%	0.39	35.38
Lupin	1,09,553.00	19.83	4.71	27.01%	0.03	27.44%	3.51	0.78%	0.61	129.18
Mankind Pharma	1,05,607.00	1.05	0.12	12.65%	0.42	12.97%	5.05	0.05%	0.54	49.37
Dr. Reddy's Laboratories	97,364.90	30.58	2.56	11.07%	0.18	12.54%	377.96	0.69%	0.41	38.68
Aurobindo Pharma	88,508.40	25.27	2.34	9.25%	0.19	11.76%	391.14	0.26%	0.48	41.58
Laurus Labs	84,727.30	60.26	10.10	18.21%	0.40	16.70%	97.21	0.12%	0.64	13.72

Strides Pharma Science Financials

Full statement

Income Statement · Consolidated

Income Statement · Consolidated — all values in INR Crore
Particulars	Mar 2026	Mar 2025	Mar 2024	Mar 2023
Revenue	₹4,858.68	₹4,565.34	₹3,890.13	₹3,688.39
Other Income	₹150.71	₹58.72	₹39.70	₹90.33
Total Revenue	₹5,009.40	₹4,624.06	₹3,929.83	₹3,778.72
Total Expenses	₹4,314.34	₹4,203.63	₹3,801.61	₹3,762.60
Profit Before Tax	₹668.69	₹486.92	-₹114.79	-₹286.20
Tax	₹94.17	₹77.52	₹29.11	-₹55.30
Profit After Tax	₹574.52	₹409.41	-₹143.90	-₹230.90
EPS - Basic	₹60.34	₹390.55	-₹7.76	-₹22.49
EPS - Diluted	₹60.34	₹390.50	-₹7.76	-₹22.49

Cash Flow · Consolidated

Cash Flow · Consolidated — all values in INR Crore
Particulars	Mar 2026	Mar 2025	Mar 2024	Mar 2023
Profit before tax	₹668.69	₹3,675.03	-₹62.72	-₹267.63
Income before WC changes	₹874.08	₹790.91	₹755.55	₹414.56
Change in Assets	-₹411.17	-₹278.51	₹69.79	-₹355.52
Change in Liabilities	₹310.72	₹104.93	-₹148.53	-₹102.28
Change in WC	-₹100.45	-₹173.58	-₹78.73	-₹457.80
Cash flow from Operations	₹702.52	₹684.37	₹701.07	₹44.41
Cash flow from Investing	-₹173.04	-₹89.69	-₹150.25	₹302.47
Cash flow from Financing	-₹453.41	-₹642.58	-₹693.32	-₹213.92
Total Cash Flow	₹76.07	-₹47.90	-₹142.51	₹132.96
Cash (Start of the year)	₹112.56	₹161.02	₹303.50	₹170.73
Cash (End of the year)	₹188.70	₹112.56	₹161.02	₹303.50

Balance Sheet · Consolidated

Balance Sheet · Consolidated — all values in INR Crore
Particulars	Mar 2026	Mar 2025	Mar 2024	Mar 2023
Non-Current Assets	₹3,313.89	₹2,949.81	₹2,870.76	₹3,395.06
Current Assets	₹3,613.34	₹3,098.91	₹2,969.00	₹3,243.36
Total Assets	₹6,927.23	₹6,048.73	₹5,839.76	₹6,638.42
Current Liabilities	₹2,895.49	₹2,591.52	₹2,879.26	₹2,990.20
Net Current Asset	₹717.85	₹507.39	₹89.74	₹253.16
Non-Current Liabilities	₹882.40	₹870.74	₹888.79	₹1,475.34
Equity Capital	₹3,149.34	₹2,586.46	₹2,071.71	₹2,172.88
Total Equity & Liabilities	₹6,927.23	₹6,048.73	₹5,839.76	₹6,638.42

Income Statement · Standalone

Income Statement · Standalone — all values in INR Crore
Particulars	Mar 2026	Mar 2025	Mar 2024	Mar 2023
Revenue	₹2,180.14	₹2,139.42	₹1,866.12	₹1,854.50
Other Income	₹123.06	₹46.19	₹58.71	₹84.07
Total Revenue	₹2,303.20	₹2,185.61	₹1,924.83	₹1,938.56
Total Expenses	₹2,100.10	₹2,107.50	₹1,942.40	₹1,988.32
Profit Before Tax	₹203.10	₹78.08	-₹22.93	-₹64.76
Tax	₹19.47	₹18.93	₹1.34	-₹69.44
Profit After Tax	₹183.64	₹59.16	-₹24.28	₹4.68
EPS - Basic	₹19.92	₹313.68	₹4.90	₹0.52
EPS - Diluted	₹19.92	₹313.65	₹4.89	₹0.52

Cash Flow · Standalone

Cash Flow · Standalone — all values in INR Crore
Particulars	Mar 2026	Mar 2025	Mar 2024	Mar 2023
Profit before tax	₹203.10	₹2,905.14	₹40.99	-₹64.76
Income before WC changes	₹248.66	₹287.25	₹291.89	₹108.11
Change in Assets	-₹166.78	₹34.32	-₹244.22	₹20.63
Change in Liabilities	₹197.26	-₹22.61	-₹115.39	₹13.18
Change in WC	₹30.48	₹11.72	-₹359.60	₹33.81
Cash flow from Operations	₹277.85	₹421.48	-₹14.01	₹241.74
Cash flow from Investing	-₹69.07	-₹137.59	-₹69.57	-₹182.58
Cash flow from Financing	-₹198.93	-₹370.32	₹93.34	₹10.82
Total Cash Flow	₹9.84	-₹86.42	₹9.77	₹69.98
Cash (Start of the year)	₹6.33	₹92.75	₹82.11	₹12.12
Cash (End of the year)	₹16.17	₹6.33	₹92.75	₹82.11

Balance Sheet · Standalone

Balance Sheet · Standalone — all values in INR Crore
Particulars	Mar 2026	Mar 2025	Mar 2024	Mar 2023
Non-Current Assets	₹3,022.13	₹2,885.44	₹3,490.70	₹3,493.34
Current Assets	₹2,373.59	₹2,145.50	₹2,411.18	₹2,126.40
Total Assets	₹5,395.72	₹5,030.95	₹5,901.87	₹5,619.74
Current Liabilities	₹1,840.07	₹1,629.61	₹2,085.14	₹1,796.83
Net Current Asset	₹533.52	₹515.89	₹326.04	₹329.58
Non-Current Liabilities	₹272.13	₹208.60	₹289.13	₹367.86
Equity Capital	₹3,283.52	₹3,192.74	₹3,527.60	₹3,455.05
Total Equity & Liabilities	₹5,395.72	₹5,030.95	₹5,901.87	₹5,619.74

* All values are in INR Crore

Qty

Bid

1020

Ask

Qty

Bid Total: 9

Ask Total: 0

Buy orders: 100%

Sell orders: 0%

30 levels of bid & ask depth

Supply & Demand Zones

Bearish

Neutral

Bullish

Slightly Bearish

by SEBI experts available for this stock

Earn more using advisory

by SEBI experts

Expert Pick

EXPPICK

Stop-loss

Entry price

Target

Indicator

Value

Verdict

RSI (14)

37.59

Neutral

ATR (14)

38.2

Neutral

STOCH(9,6)

30.98

Neutral

STOCH RSI (14)

Bullish

ADX(9)

45.7

Bearish

UO(9)

47.46

Neutral

ROC(12)

-8.56

Bearish

WillR(14)

-77.61

Neutral

Period

Simple value

Exponential vaue

1039.82

1036.42

10D

1052.79

1050.76

20D

1078.04

1065.88

50D

1091.15

1069.14

100D

1032.75

1040.94

About Strides Pharma Science

ISIN

INE939A01011

Sector Market Cap

₹ 9,392.4 Cr

Strides Pharma Science Limited is an India-based pharmaceutical company. The Company is focused on the development and manufacture of IP-led niche finished dosage formulations. The Company operates through two segments: Pharmaceutical and Bio-pharmaceutical. Its geographical segment includes Africa, Australia, Asia (excluding India), North America, Europe, India, and Others. The Company manufactures a range of niche and pharmaceutical products, including a range of dosage forms such as liquids, creams and ointments, soft gels, sachets, tablets, and modified release dosage formats. It has eight manufacturing units located in India (Bengaluru-two sites, Puducherry, and Chennai), Singapore, Italy (Milan), the United States (Florida) and Kenya (Nairobi). It is also engaged in manufacturing soft gelatin capsules. It develops and manufactures drugs in the anti-retroviral, anti-malarial, anti-tuberculosis, hepatitis, and other infectious disease drug segments for its institutional business.

Strides Pharma Science Financial Highlights

Revenue: Strides Pharma Science reported revenue of ₹5,009.39 crore in FY26 vs ₹4,624.06 crore in FY25. It showed an increase of 8.33% on a yearly basis.
Operating Profit: Strides Pharma Science reported an operating profit of ₹668.69 crore in FY26 vs ₹486.92 crore in FY25. It showed an increase of 37.33% on a year-on-year basis.
Net Profit: Strides Pharma Science reported a net profit of ₹574.52 crore in FY26 vs ₹3,597.51 crore in FY25. It showed a decrease of 84.03% on a yearly basis.

Strides Pharma Science Quarterly Result Highlights

Strides Pharma Science reported revenue of ₹1,331.60 crore in Mar 2026, compared with ₹1,301.51 crore in Dec 2025, representing an increase of 2.31% on a quarter-on-quarter (QoQ) basis.
Strides Pharma Science reported an operating profit of ₹148.05 crore in Mar 2026, compared with ₹245.48 crore in Dec 2025, representing a decrease of 39.69% on a quarter-on-quarter (QoQ) basis.
Strides Pharma Science reported a profit of ₹129.28 crore in Mar 2026, compared with ₹208.12 crore in Dec 2025, reflecting a decrease of 37.88% on a QoQ basis.
The earnings per share (EPS) of Strides Pharma Science stood at ₹60.34 during Mar 2026.